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Ring chromosome 10 is a rare cytogenetic finding. Only a few cases with molecular cytogenetic definition have
been reported. We report here on a child with a ring chromosome 10, which is associated with prenatal and
postnatal growth retardation, microcephaly, dysmorphic features, hypotonia, heart defect, severe pes equinovarus,
and bronchial asthma. The chromosomal aberration was defined by chromosome microarray analysis, which
revealed two deletions at 10pter (3.68 Mb) and 10qter (4.26 Mb). The clinical features are very similar to those
reported in other clinical cases with ring chromosome 10, excluding bronchial asthma, which has not been
previously reported in individuals with ring chromosome 10.
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Constitutional ring chromosomes have been identified
for each of the human chromosomes, and overall fre-
quency is estimated at 1 in 30,000 to 60,000 births [1].
Rings result from rare intrachromosomal fusions, al-
though the mechanisms underlying chromosomal ring
formation are not completely understood.
Ring chromosome 10 is a rare cytogenetic finding, cur-
rently reported in 17 unrelated patients. Common clin-
ical features in these patients include short stature,
intellectual disability, microcephaly, facial dysmorphism,
and ophthalmologic and urinary tract abnormalities [2].
Clinical features vary, however, depending on the pos-
ition of the breakpoints and on the level of mosaicism
resulting from the unstable nature of the ring upon cell
division [3]. Thus, a comprehensive diagnosis of an
individual with a ring chromosome requires both a mo-
lecular diagnostic approach such as array-CGH and a
cytogenetic approach to determine a specific individual
diagnosis. Here we describe the clinical features of the
patient with the largest apparently stable ring chromo-
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The patient is a 13-month-old girl born at 36 weeks of
gestation to non-consanguineous and healthy Caucasian
parents aged 27 years (mother) and 33 years (father). In
utero, intra-uterine growth retardation with meconium
staining in the amniotic fluid was observed. She was de-
livered by elective caesarean section. At birth her weight
was 1,600 g (−2.5 SD), her length was 40 cm (-2.5 SD),
and the head circumference was 30 cm (−1 SD). Apgar
scores were 4–8. Severe congenital pes equinovarus was
detected from birth. She was also noted to have hypo-
tonia. Shortly after birth, treatment with the Ponseti
method was started with surgical correction of the
Achilles tendon at 3 months of age. Neurosonoscopy re-
vealed mild widening of the ventricles, but re-evaluation
after 1 month was normal. She was found to have
normal hearing acuity after birth. A cardiac ultrasound
examination showed a large patent ductus arteriosus.
She had no feeding difficulties. Abdominal organs were
without structural abnormalities. At the age of 4 months,
bronchial asthma was diagnosed and she has been
receiving medical treatment ever since. Examination at
the age of 7 months revealed delayed speech and gross
motor skills. Her height, weight, and head circumfer-
ence were significantly less than the 3rd percentile.
Furthermore, the patient had dysmorphic features con-
sisting of microcephaly, slight metopic ridge, low-setral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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broad nasal bridge, stubby nose, smooth philtrum with
thin upper lip and everted lower lip, microstomia,
narrow palate, short neck, inverted and widely-spaced
nipples, broad hands, tapering fingers, single palmar
crease on the left palm, and broad feet with short toes
and small nails (Figure 1). Mild divergent strabismus
was documented at that time. Otolaryngological evalu-
ations revealed a deviated septum. Skull roentgeno-
grams revealed no synostosis.
On the last examination at 13 months of age, her
development milestones were found to be delayed. She
could not sit unsupported and her head control was
insufficient. She showed good visual fixation. There was
no speech development. Muscle tone was decreased and
deep tendon reflexes were normal. She displayed un-
usual repetitive hand movements, continuously pressing
her palms together in the midline and repetitively
stroking her thumbs. A brain MRI was declined by her
parents. At the age of 7 months, the proband was re-
ferred to a clinical geneticist.
Materials and methods
Standard cytogenetics
Cultures of the patient’s peripheral blood were estab-
lished and harvested according to standard laboratory
protocols. Chromosome preparations were treated with
trypsin and stained with Giemsa. A total of 30 meta-
phase cells were analysed at the 550-band resolution
level. The karyotypes were described according to the
guidelines of the International System for Human
Cytogenetic Nomenclature [46,XX,r(10)(p15.1q26.1)].
Additionally, 370 cells were counted to verify ring in-
stability. The parents declined to undergo chromo-
somal analysis.Figure 1 Photographs of the patient at the age of 7 months (frontal
and lateral view). Note the downslanting and narrowing of palpebral
fissures, broad nasal bridge, stubby nose, smooth philtrum with thin
upper lip and everted lower lip, microstomia, low-set ears, and
short neck.Molecular cytogenetics
DNA was extracted from the patient’s peripheral white
blood cells using the phenol-chloroform extraction
method. A subsequent array-comparative genomic hy-
bridisation (array-CGH) test was performed to deter-
mine the chromosomal breakpoints of the ring, as well
as other possible chromosomal abnormalities that may
have been missed by routine G-banded chromosomal
analysis. Agilent Human ISCA CGH 180 K microarrays
with an average spatial resolution of 25 kb were used in
the study (Agilent Technologies, Santa Clara, CA). Gen-
omic DNA from the proband and pooled normal male
reference DNA (Agilent Technologies) were digested
with Covaris S220 (Life Technologies, Grand Island,
NY) and labelled with an Agilent Genomic DNA label-
ling kit according to the manufacturer’s recommenda-
tions. Patient and reference DNA were labelled with
Cy5 and Cy3 respectively and were co-hybridised to arrays
for 24 h at 67°C in a rotating oven (Agilent technologies)
at 20 rpm. The arrays were then washed and scanned with
an Agilent Microarray Scanner. Data were extracted using
Feature Extraction 10.7.1 software (Agilent Technologies)
and analysed using Cytogenomics 2.9.2.4 software (Agilent
Technologies). Genomic copy number changes were iden-
tified with the assistance of the Aberration Detection
Method 2 algorithm with the sensitivity threshold set at
6.0. Copy number changes identified in the samples were
evaluated by using the UCSC Genome Browser website
(http://genome.ucsc.edu) and the Database of Genomic
Variants (http://projects.tcag.ca/variation). The array data
was analysed using annotation GRCh37/hg19. The DE-
CIPHER (http://decipher.sanger.ac.uk/) database was used
to support genotype-phenotype correlation.Results
Cytogenetic analysis revealed an apparently stable non-
mosaic ring chromosome 10 [46,XX,r(10) (p15.1q26.1)].
Secondary aberrations (two separate rings and interlocked
rings) were found in less than 5% of the mitoses counted,
1.7% and 0.5% respectively. High-resolution breakpoint
mapping with a Human ISCA CGH 180 K microarray
re-defined the karyotype as 46,XX,r(10)(p15.2q26.3).arr
[hg19]10p15.3p15.2(1–3,678,763)×1,10 q26.3(131,276,836–
135,534,747)×1, indicating an approximately 3.68 Mb
deletion in 10p and a 4.26 Mb deletion in 10q (Figure 2).
No other relevant genomic imbalance was found.Discussion
Ring chromosome 10 is a rare disorder. Only seventeen
cases of ring chromosome 10 have been reported
in literature and mostly defined by G banding [3-15]
and only four cases with molecular cytogenetic definition
[2,16,17]. This is the fifth case with precisely defined
Figure 2 Chromosome 10 array-CGH profile of the patient showing a 3.68 Mb deletion at 10pter and a 4.26 Mb deletion at 10qter. A comparison
of the extension of the deletions with previously reported patients with ring chromosome 10 is also shown (white bars).
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correlation.
We compared the phenotype and genotype of our
patient with previously published patients having pre-
cisely defined breakpoints [2,16,17]. The patient we
present has the largest ring chromosome 10 reported to
date. In all previously reported patients with ring chromo-
some 10, the breakpoints in 10q are variable but more
proximal to the centromere (Figure 2).
Common clinical features in patients with ring
chromosome 10 include prenatal and postnatal growth
retardation, varying degrees of intellectual disability,
microcephaly, and dysmorphic features (broad nasal
bridge, strabismus, hypertelorism, low-set malformed
ears) [18,19] that are non-specific to distal 10q deletion
and are common to many chromosome anomalies. It is
unlikely that 3.68 Mb terminal 10p15.2 deletion in the
present ring chromosome or smaller deletion in case of
ring chromosome reported by Gunnarson et al. would
make a significant contribution to the phenotype. How-
ever the patient with a larger deletion of chromosome
10 short arm has additional clinical features such as
talipes equinovarus, hepatomegaly, splenomegaly that
cause severe phenotype [17].
We also compared the clinical features of our patient
with patients from DECIPHER (Table 1). Cases with
complex chromosomal rearrangements or with larger
deletions than those identified in our patient and cases
without a detailed clinical description were excluded
from the comparison. Based on comparison of the clin-
ical features of our patient with the clinical features ofthe patients with ring chromosome and the clinical fea-
tures of patients with pure terminal deletions of 10p and
10q, the contribution of the terminal deletion 10q to the
clinical phenotype of our patient is the most significant.
The study of patients with a distal pure 10q deletion
has revealed the existence of a minimal critical region
(MCR), which was recently assigned by Yatsenko et al.
[20] to an approximately 600 kb segment in the distal
part of chromosome 10, which encompasses two anno-
tated genes, C10ORF90 (chromosome 10 open reading
frame 90) and DOCK1 (dedicator of cytokinesis 1). We
predict that the overlapping phenotype of pure 10q dele-
tions at 10q26.2 region could be caused by haploinsuffi-
ciency of one or more genes or position effect, since
10q26.3 deletion detected in our patient does not involve
these genes.
The deleted region 10q26.3, 4.26 Mb in size, contains
31 protein coding genes of which PPP2R2D (protein
phosphatase 2, regulatory subunit B, delta), JAKMIP3
(Janus kinase and microtubule interacting protein 3),
DPYSL4 (dihydropyrimidinase-like 4), INPP5A (inositol
polyphosphate-5-phosphatase), GPR123 (G protein-coupled
receptor 123), GLRX3 (glutaredoxin 3) and ADAM8
(ADAM metallopeptidase domain 8) could be considered
important contributors to the clinical phenotype. Based
upon function and high expression in the brain [http://
www.proteinatlas.org/], we suggest that the haploinsuf-
fiency of PPP2R2D, JAKMIP3, DPYSL4, and GPR123 could
play significant roles in neurodevelopmental delay.
PPP2R2D is essential for many signal transduction path-
ways [21]. JAKMIP3 is associated with caveolin-1, which
Table 1 Comparison of clinical features associated with pure 10p deletions and pure 10q deletions published in DECIPHER
Deletion interval,
hg19















10:269607-1380732 ZMYND11, DIP2C, PRR26, LARP4B, GTPBP4, IDI2,
WDR37, ADARB2-AS1
1.11 + - - - + + 1232
10:136361-1758581 ZMYND11, DIP2C, PRR26, LARP4B, GTPBP4, IDI2,
WDR37, ADARB2-AS1
1.62 + + - - + - 2319
10:299304-740247 ZMYND11, DIP2C, PRR26 0.44 + + + - - - 270190
10:723328-1214416 DIP2C, PRR26, LARP4B, GTPBP4, IDI2 0.49 + - - - - - 271618
10:148206-2461302 ZMYND11, DIP2C, PRR26, LARP4B, GTPBP4, IDI2,
WDR37, ADARB2-AS1
2.31 + - - - - - 274302
10:158945-313504 ZMYND11 0.15 + + - + + - 248177
10:148206-1232090 ZMYND11, DIP2C, PRR26, LARP4B, GTPBP4, IDI2,
WDR37, ADARB2-AS1




MGMT, EBF3, GLRX3, TCERG1L, PPP2R2D, BNIP3,
JAKMIP3, DPYSL4, STK32C, LRRC27, PWWP2B,
C10orf91, INPP5A, NKX6-2, C10orf93, GPR123,
KNDC1, UTF1, VENTX, ADAM8, TUBGCP2, ZNF511,
CALY, PRAP1, C10orf125, ECHS1, PAOX, MTG1,
SPRN, CYP2E1, SYCE1, SPRNP1
3.90 - + + - - - 3452
loss 10:135057537-
135434113
ADAM8, TUBGCP2, ZNF511, CALY, PRAP1, C10orf125,
ECHS1, PAOX, MTG1, SPRN, CYP2E1, SYCE1, SPRNP1
0.38 + - - - - + 263009
loss 10:135053398-
135404523
VENTX, ADAM8, TUBGCP2, ZNF511, CALY, PRAP1,
C10orf125, ECHS1, PAOX, MTG1, SPRN, CYP2E1, SYCE1
0.35 - - - - - - 286726
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transduction of a variety of neurotransmitter and neuro-
trophic receptors in the central nervous system (CNS)
[22]. The collapsin response mediator protein encoded by
DPYSL4 is thought to be involved in semathorin-induced
growth cone collapse during neural development.
Down-regulation of DPYSL4 expression using siRNA
shows an early increase in neurite outgrowth, further
supporting the idea that DPYSL4 inhibits microtubule
polymerisation and neurite outgrowth [23]. The CNS-
specific expression of GPR123, together with the high se-
quence conservation between the vertebrate sequences in-
vestigated, indicate that GPR123 may have an important
role in the regulation of neuronal signal transduction [24].
Craniofacial dysmorphisms, foot abnormalities, and
short stature could be attributed to the loss of the
GLRX3 gene. Although growth delay is usually associ-
ated with the ring chromosome of any autosome, pos-
sibly due to ring instability [1], stature might also
correlate with the haploinsuffiency of genes that encode
protein and play a role in cell growth. The ubiquitous
expression of Glrx3 in mouse embryos and tissues indi-
cates that Glrx3 is required for cell growth, organ devel-
opment, and normal metabolism during growth and
development [25]. Thus, deletion of GLRX3 might in-
fluence the severity of growth delay. The patent ductus
arteriosus could be associated with the haploinsuf-
fiency of DPYSL4, PPP2R2D, and INPP5A, the expres-
sion of which is predominant in the heart [http://
www.proteinatlas.org/].
The second deleted region, 10p15.2-pter, could also
contribute to the observed phenotype. The 10p15.3p15.2
deleted region contains 11 protein-coding genes (TUBB8
(tubulin, beta 8 class VIII), ZMYND11 (zinc finger, MYND-
type containing 11), DIP2C (DIP2 disco-interacting protein
2 homolog C), PRR26 (proline rich 26), LARP4B (La ribo-
nucleoprotein domain family, member 4B), GTPBP4 (GTP
binding protein 4), IDI2 (isopentenyl-diphosphate delta
isomerase 2), WDR37 (WD repeat domain 37), ADARB2-
AS1 (ADARB2 antisense RNA 1), PFKP (phosphofructoki-
nase, platelet), PITRM1 (pitrilysin metallopeptidase 1), from
which DIP2C and ZMYND11 could be considered import-
ant contributors to growth delay, since they were most
commonly deleted in DECIPHER patients with common
clinical features, short stature and microcephaly (Table 1).
ZMYND11 [26] and DIP2C [27] are expressed in various
tissues, including the brain, but little is known about their
function. Gunnarson et al. stated that loss of 10p15.3 re-
gion including ZMYND11 would contribute little to the
clinical phenotype because of significant larger terminal de-
letion at 10q [16]. However ZMYND11 was suggested by
DeScipio et al. as a main contributor to the clinical features
associated with 10p15 deletions based on genotype-
phenotype of the cases with isolated 10p deletions [28].In addition to the clinical features commonly found in
patients with ring chromosome, bronchial asthma was
present in our patient. This clinical feature had not pre-
viously been reported in patients with ring chromosome
10. The ADAM8 mapped at 10q26 could be involved in
asthma pathogenesis. In humans, ADAM8 is expressed
by most leukocytes [29,30], lung epithelial cells [31],
and osteoclasts [32]. More recently, ADAM8 has been
strongly associated with allergic airway inflammation
(AAI) in humans and mice, and additional studies of
ADAM8 are beginning to shed light on its roles in
asthma pathogenesis [33].Conclusions
The case reported here together with clinical and molecu-
lar findings, compared to previously published cases, high-
lights the importance of microarray analysis for patients
with ring chromosomes, since it helps to delineate spe-
cific phenotypes. We were able to determine the gene
content of the regions and make karyotype-phenotype
correlations after having refined the exact breakpoints
of the deletions. Further functional studies of candidate
genes are needed to prove biological significance in
growth and development.Consent
This case report is presented with the informed consent
of the patient’s parents. A copy of the written consent is
available for review by the editor-in-chief of this journal.
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